Table 1.
Physico-chemical characteristics of SPION used in the treatment of brain aging diseases
| Neurological disorder | Ref | SPION
|
Developer | |||
|---|---|---|---|---|---|---|
| Iron oxide | [Fe] mg/mL | Core/hydrodynamic size (nm) | Coating agent | |||
| Stroke | 76 | SPIO | N/A | N/A/N/A | N/A | N/A |
| 15 | SPIO | N/A | N/A/N/A | N/A | N/A | |
| 75 | Fe3O4 | ~87.5×10−3 | 12.2/152.8 | meso-2,3-Dimercaptosuccinic acid – poly-l-lysine | Synthesized | |
| 72 | Fe3O4 | 50.0 | 8.6/182 | Starch | FluidMAG-D (Chemicell GmbH, Berlin, Germany) | |
| Fe3O4 | 25.0 | 11.3/121 | Phosphatidylcholine | FluidMAG-lipid (Chemicell GmbH, Berlin, Germany) | ||
| Fe3O4 | 25.0 | 9.6/176 | DEAE-starch | FluidMAG-DEAE (Chemicell GmbH, Berlin, Germany) | ||
| Fe3O4 | 35.0 | 8.6/162 | Diphosphate | FluidMAG-P (Chemicell GmbH, Berlin, Germany) | ||
| Fe3O4 | 50.0 | 11.5/175 | Poly-diallyl-dimethylamine | FluidMAG-Q (Chemicell GmbH, Berlin, Germany) | ||
| FeO1.44 | 16.0 | 6.9/118 | Dextran | Endorem™(Guerbet, Roissy, France) | ||
| Fe3O4/γ-Fe2O3 | 56.0 | 9.1/62 | Dextran | Ferucarbotran (Meito Sangyo Co. LTD., Japan) | ||
| 65 | Fe3O4 | N/A | 10/50 | Dextran | CD34 Nanobeads, QBEND-10 antibody (mouse antihuman CD34) (MACS, MiltenyiBiotec, Bergisch, Gladbach, Germany) | |
| 77 | Fe3O4 | 150×10−3 | 6/150 | PEG-PGA-coated nanovesicle | Synthesized SPION by modified polyol method; Preparation of PEI-SA vesicles; PEG-PGA coating of PEI-SA vesicles | |
| 64 | Fe3O4 | 10.0 | N/A/900 | Carboxylated iron oxide core and carried Dragon Green Fluorophore | M-SPIO (IFPs, Bangs Laboratory, Fishers, IN, USA) | |
| 63 | Fe3O4 | N/A | 76–80/120 | Silica-rhodamine | FMNC* (synthesized by two steps: synthesis of PMNC** and coating of PMNC with 2 layers of silica sandwiched with a layer of rhodamine) | |
| 71 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Endorem™ (Guerbet, Roissy, France) | |
| 73 | Fe3O4/γ-Fe2O3 | 27.9 | 4/55–65 | Carboxydextran | Resovist® (Bayer Schering Pharma AG, Berlin, Germany) | |
| 62 | Fe3O4 | N/A | 6/65 | Chitosan | Synthesized by sonochemical method followed by chitosan coating process | |
| 14 | Fe3O4/γ-Fe2O3 | 27.9 | 4/55–65 | Carboxydextran | Resovist® (Bayer Schering Pharma AG, Berlin, Germany) | |
| FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Endorem™ (Guerbet, Roissy, France) | ||
| Fe3O4 | 20.0 | 5–6/20–40 | Dextran T10 | Sinerem® (Guerbet, Roissy, France) | ||
| 70 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Feridex® (Advanced Magnetic, Cambridge, MA USA) | |
| 13 | Iron oxide | N/A | 5/87–766 | N/A | Synthesized MGIO (polymerization and coprecipitation) | |
| Fe3O4/γ-Fe2O3 | 27.9 | 4.2/64 | Carboxydextran | Ferucarbotran – Resovist® (Bayer Schering Pharma AG, Berlin, Germany) | ||
| 12 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Feridex® (Advanced Magnetic, Cambridge, MA USA) | |
| 69 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran | Feridex® (Berlex Laboratories, Wayne, NJ, USA) | |
| 68 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Feridex® (Advanced Magnetic, Cambridge, MA USA) | |
| 67 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Feridex® (Berlex Laboratories, Wayne, NJ, USA) | |
| 66 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Endorem™ (Guerbet, Roissy, France) | |
| 74 | Fe3O4 | 20.0 | 5–6/20–40 | Dextran | Sinerem® (Guerbet, Roissy, France) | |
| Parkinson’s | 25 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Feridex® (Advanced Magnetic, Cambridge, MA USA) |
| 24 | Fe3O4/γ-Fe2O3 | 27.9 | 4/55–65 | Carboxydextran | Resovist® (Bayer Schering Pharma AG, Berlin, Germany) | |
| 22 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Feridex® (Advanced Magnetic, Cambridge, MA USA) | |
| 21 | USPIO | 2.5 | N/A/(15–20) | Dextran | Synthesized (IODEX-TAT-FITC)*** | |
| 23 | Fe3O4 | 27.9 | 5/9 | Monomercitrate | VSOP (C200, Ferropharm, Teltow, Germany) | |
| 20 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Feridex® (Advanced Magnetic, Cambridge, MA USA) | |
| 19 | Iron oxide# | 3.01 | N/A/79 | DPPA Na – F108& | Synthesized | |
| Sclerosis | 31 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Endorem™ (Guerbet, Roissy, France) |
| 33 | USPIO | 2.0 | 8/35 | N/A | Molday ION Rhodamine B (BioPAL Inc, Worcester, MA USA) | |
| 32 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Endorem™ (Guerbet, Roissy, France) | |
| 34 | FeO1.44 | 11.2 | 5–6/50–180 | Dextran T10 | Feridex® (Advanced Magnetic, Cambridge, MA USA) | |
| 30 | Fe3O4 | 11.2 | N/A/80–150 | Dextran T10 | Feridex® (Advanced Magnetic, Cambridge, MA USA) | |
| Fe3O4/γ-Fe2O3 | 27.9 | N/A/62 | Carboxydextran | Resovist® (Bayer Schering Pharma AG, Berlin, Germany) | ||
| Fe3O4 | 20.0 | 5–6/20–40 | Dextran | Sinerem® (Guerbet, Roissy, France) | ||
Notes:
Not specific of the iron oxide crystal phase
dipalmitoylphosphatidic acid sodium salt (DPPA Na) “ethylene oxide-propyleneoxide block copolymer” (F108) prepared by Bracco Research (Geneva, Switzerland)
Polystyrene magnetite nanocluster (PMNC)
FMNC, fluorescent-magnetite-nanocluster
Iron oxide nanoparticles coated with dextran (IODEX) conjugated with TAT-fluoresceinisothiocyanate (FITC) peptide.
Abbreviation: N/A, not identified; Ref, reference; SPIO, superparamagnetic iron oxide; SPION, superparamagnetic iron oxide nanoparticles; USPIO, ultra small iron oxide particles; DEAE, diethylamine ethyl; PEI-SA, stearic acid - grafted polyethyleneimine copolymer; PEG-PGA, poly (ethylene glycol)-poly (L-glutamic acid); MGIO, microgel iron oxide; VSOP, very small superparamagnetic iron oxide particles; M-SPIO, micrometer superparamagnetic iron oxide; IFPs, iron fluorescent particles.